Biosynex Valuation
| ALBIO Stock | EUR 2.88 0.06 2.13% |
Based on Macroaxis valuation methodology, the firm appears to be fairly valued. Biosynex shows a prevailing Real Value of €2.87 per share. The current price of the firm is €2.88. Our model approximates the value of Biosynex from analyzing the firm fundamentals such as Current Valuation of 91.77 M, profit margin of 0.21 %, and Return On Equity of 0.89 as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Biosynex's price fluctuation is risky at this time. Calculation of the real value of Biosynex is based on 3 months time horizon. Increasing Biosynex's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Biosynex's intrinsic value may or may not be the same as its current market price of 2.88, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.88 | Real 2.87 | Hype 2.88 | Naive 3.16 |
The intrinsic value of Biosynex's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biosynex's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biosynex helps investors to forecast how Biosynex stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biosynex more accurately as focusing exclusively on Biosynex's fundamentals will not take into account other important factors: Biosynex Total Value Analysis
Biosynex is presently projected to have takeover price of 91.77 M with market capitalization of 121.6 M, debt of 29.16 M, and cash on hands of 1.98 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biosynex fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
91.77 M | 121.6 M | 29.16 M | 1.98 M |
Biosynex Investor Information
About 58.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.77. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biosynex recorded earning per share (EPS) of 6.37. The entity last dividend was issued on the 16th of May 2022. The firm had 697:694 split on the 5th of July 2017. Based on the key measurements obtained from Biosynex's financial statements, Biosynex is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Biosynex Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biosynex has an asset utilization ratio of 142.23 percent. This connotes that the Company is making €1.42 for each dollar of assets. An increasing asset utilization means that Biosynex is more efficient with each dollar of assets it utilizes for everyday operations.Biosynex Ownership Allocation
The market capitalization of Biosynex is €121.6 Million. Biosynex retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Note, that even with substantial debt, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company at some point.Biosynex Profitability Analysis
The company reported the revenue of 382.53 M. Net Income was 104 M with profit before overhead, payroll, taxes, and interest of 206.41 M.About Biosynex Valuation
The stock valuation mechanism determines Biosynex's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Biosynex based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biosynex. We calculate exposure to Biosynex's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biosynex's related companies.Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France. BIOSYNEX is traded on Paris Stock Exchange in France.
8 Steps to conduct Biosynex's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Biosynex's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biosynex's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biosynex's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biosynex's revenue streams: Identify Biosynex's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biosynex's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biosynex's growth potential: Evaluate Biosynex's management, business model, and growth potential.
- Determine Biosynex's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biosynex's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Biosynex Stock Analysis
When running Biosynex's price analysis, check to measure Biosynex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosynex is operating at the current time. Most of Biosynex's value examination focuses on studying past and present price action to predict the probability of Biosynex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosynex's price. Additionally, you may evaluate how the addition of Biosynex to your portfolios can decrease your overall portfolio volatility.